Which has preferable earnings & valuation, SRRK or AVBP?

Scholar Rock is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.59 N/A ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A

Is SRRK or AVBP more profitable?

ArriVent BioPharma's return on equity of -48.98% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% ArriVent BioPharma N/A -48.98% -45.44%

Does the media favor SRRK or AVBP?

In the previous week, Scholar Rock had 4 more articles in the media than ArriVent BioPharma. MarketBeat recorded 6 mentions for Scholar Rock and 2 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.89 beat Scholar Rock's score of 1.30 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer AVBP or CRSP?

In the previous week, CRISPR Therapeutics had 10 more articles in the media than ArriVent BioPharma. MarketBeat recorded 12 mentions for CRISPR Therapeutics and 2 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.89 beat CRISPR Therapeutics' score of 0.86 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CRISPR Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CGON or AVBP more profitable?

CG Oncology's return on equity of -23.33% beat ArriVent BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% ArriVent BioPharma N/A -48.98% -45.44%

Does the media favor CGON or AVBP?

In the previous week, CG Oncology had 8 more articles in the media than ArriVent BioPharma. MarketBeat recorded 10 mentions for CG Oncology and 2 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.89 beat CG Oncology's score of 0.54 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is XENE or AVBP more profitable?

ArriVent BioPharma's return on equity of -48.98% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Xenon Pharmaceuticals N/A -49.23% -46.42% ArriVent BioPharma N/A -48.98% -45.44%

Does the media favor XENE or AVBP?

In the previous week, Xenon Pharmaceuticals had 5 more articles in the media than ArriVent BioPharma. MarketBeat recorded 7 mentions for Xenon Pharmaceuticals and 2 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.89 beat Xenon Pharmaceuticals' score of 0.49 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

ArriVent BioPharma (AVBP) Competitors

$30.54 +0.34 (+1.13%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$30.54 0.00 (-0.02%)

As of 06/12/2026 04:10 PM Eastern

Compare

AVBP vs. SRRK, GRFS, CRSP, CGON, and XENE

Should you buy ArriVent BioPharma stock or one of its competitors? MarketBeat compares ArriVent BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ArriVent BioPharma include Scholar Rock (SRRK), Grifols (GRFS), CRISPR Therapeutics (CRSP), CG Oncology (CGON), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry.

How does ArriVent BioPharma compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

In the previous week, Scholar Rock had 4 more articles in the media than ArriVent BioPharma. MarketBeat recorded 6 mentions for Scholar Rock and 2 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.89 beat Scholar Rock's score of 1.30 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 13.3% of Scholar Rock shares are held by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Scholar Rock has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

Scholar Rock presently has a consensus price target of $56.00, suggesting a potential upside of 26.75%. ArriVent BioPharma has a consensus price target of $43.38, suggesting a potential upside of 42.03%. Given ArriVent BioPharma's higher possible upside, analysts clearly believe ArriVent BioPharma is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Scholar Rock is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

ArriVent BioPharma's return on equity of -48.98% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Summary

ArriVent BioPharma beats Scholar Rock on 8 of the 14 factors compared between the two stocks.

How does ArriVent BioPharma compare to Grifols?

ArriVent BioPharma (NASDAQ:AVBP) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

ArriVent BioPharma currently has a consensus target price of $43.38, suggesting a potential upside of 42.03%. Grifols has a consensus target price of $10.00, suggesting a potential upside of 30.89%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe ArriVent BioPharma is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

ArriVent BioPharma has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, Grifols has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

Grifols has a net margin of 5.54% compared to ArriVent BioPharma's net margin of 0.00%. Grifols' return on equity of 6.21% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Grifols	5.54%	6.21%	2.39%

In the previous week, ArriVent BioPharma had 1 more articles in the media than Grifols. MarketBeat recorded 2 mentions for ArriVent BioPharma and 1 mentions for Grifols. ArriVent BioPharma's average media sentiment score of 1.89 equaled Grifols'average media sentiment score.

Company	Overall Sentiment
ArriVent BioPharma	Very Positive
Grifols	Very Positive

9.5% of ArriVent BioPharma shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by company insiders. Comparatively, 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Grifols has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Grifols	$8.51B	0.61	$454.82M	$0.19	40.21

Summary

ArriVent BioPharma beats Grifols on 8 of the 15 factors compared between the two stocks.

How does ArriVent BioPharma compare to CRISPR Therapeutics?

ArriVent BioPharma (NASDAQ:AVBP) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

ArriVent BioPharma has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

ArriVent BioPharma has higher earnings, but lower revenue than CRISPR Therapeutics. ArriVent BioPharma is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
CRISPR Therapeutics	$3.51M	1,368.44	-$581.60M	-$6.22	N/A

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ArriVent BioPharma has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

In the previous week, CRISPR Therapeutics had 10 more articles in the media than ArriVent BioPharma. MarketBeat recorded 12 mentions for CRISPR Therapeutics and 2 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.89 beat CRISPR Therapeutics' score of 0.86 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CRISPR Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ArriVent BioPharma currently has a consensus price target of $43.38, suggesting a potential upside of 42.03%. CRISPR Therapeutics has a consensus price target of $67.78, suggesting a potential upside of 36.10%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe ArriVent BioPharma is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

Summary

CRISPR Therapeutics beats ArriVent BioPharma on 8 of the 15 factors compared between the two stocks.

How does ArriVent BioPharma compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

CG Oncology currently has a consensus price target of $81.73, suggesting a potential upside of 37.22%. ArriVent BioPharma has a consensus price target of $43.38, suggesting a potential upside of 42.03%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe ArriVent BioPharma is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CG Oncology has higher revenue and earnings than ArriVent BioPharma. CG Oncology is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,300.30	-$160.99M	-$2.33	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

CG Oncology's return on equity of -23.33% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
ArriVent BioPharma	N/A	-48.98%	-45.44%

In the previous week, CG Oncology had 8 more articles in the media than ArriVent BioPharma. MarketBeat recorded 10 mentions for CG Oncology and 2 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.89 beat CG Oncology's score of 0.54 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

CG Oncology has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

Summary

CG Oncology beats ArriVent BioPharma on 8 of the 15 factors compared between the two stocks.

How does ArriVent BioPharma compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

ArriVent BioPharma's return on equity of -48.98% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
ArriVent BioPharma	N/A	-48.98%	-45.44%

In the previous week, Xenon Pharmaceuticals had 5 more articles in the media than ArriVent BioPharma. MarketBeat recorded 7 mentions for Xenon Pharmaceuticals and 2 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.89 beat Xenon Pharmaceuticals' score of 0.49 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

ArriVent BioPharma has lower revenue, but higher earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	671.53	-$345.91M	-$4.70	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 4.1% of Xenon Pharmaceuticals shares are held by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Xenon Pharmaceuticals has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

Xenon Pharmaceuticals currently has a consensus price target of $77.20, indicating a potential upside of 48.18%. ArriVent BioPharma has a consensus price target of $43.38, indicating a potential upside of 42.03%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

ArriVent BioPharma beats Xenon Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get ArriVent BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVBP vs. The Competition

Export

Metric	ArriVent BioPharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.41B	$3.39B	$6.75B	$12.02B
Dividend Yield	N/A	2.25%	2.66%	5.61%
P/E Ratio	-8.80	19.48	23.82	24.42
Price / Sales	N/A	304.87	510.69	109.73
Price / Cash	N/A	124.89	44.01	55.64
Price / Book	4.10	8.32	10.66	6.79
Net Income	-$166.31M	$23.89M	$3.57B	$337.66M
7 Day Performance	0.63%	3.56%	0.87%	2.56%
1 Month Performance	5.57%	-1.29%	0.18%	2.03%
1 Year Performance	31.24%	44.89%	25.23%	30.31%

ArriVent BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVBP ArriVent BioPharma	2.6281 of 5 stars	$30.54 +1.1%	$43.38 +42.0%	+29.2%	$1.41B	N/A	N/A	40	News Coverage Positive News
SRRK Scholar Rock	3.5334 of 5 stars	$44.68 -5.7%	$56.00 +25.3%	+32.6%	$5.68B	N/A	N/A	140	Positive News
GRFS Grifols	4.6167 of 5 stars	$7.63 -1.4%	$10.00 +31.1%	-14.9%	$5.27B	$8.51B	40.16	25,247	Positive News
CRSP CRISPR Therapeutics	3.5243 of 5 stars	$52.02 -4.0%	$65.47 +25.9%	+20.6%	$5.23B	$3.51M	N/A	460	Analyst Forecast
CGON CG Oncology	2.7508 of 5 stars	$55.53 -6.2%	$81.73 +47.2%	+124.8%	$5.22B	$4.04M	N/A	61

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVBP) was last updated on 6/13/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ArriVent BioPharma (AVBP) Competitors

AVBP vs. SRRK, GRFS, CRSP, CGON, and XENE

How does ArriVent BioPharma compare to Scholar Rock?

Summary

How does ArriVent BioPharma compare to Grifols?

Summary

How does ArriVent BioPharma compare to CRISPR Therapeutics?

Summary

How does ArriVent BioPharma compare to CG Oncology?

Summary

How does ArriVent BioPharma compare to Xenon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ArriVent BioPharma (AVBP) Competitors

AVBP vs. SRRK, GRFS, CRSP, CGON, and XENE

How does ArriVent BioPharma compare to Scholar Rock?

Does the media favor SRRK or AVBP?

Do insiders and institutionals believe in SRRK or AVBP?

Which has more volatility & risk, SRRK or AVBP?

Do analysts rate SRRK or AVBP?

Which has preferable earnings & valuation, SRRK or AVBP?

Is SRRK or AVBP more profitable?

Summary

How does ArriVent BioPharma compare to Grifols?

Do analysts prefer AVBP or GRFS?

Which has more risk & volatility, AVBP or GRFS?

Is AVBP or GRFS more profitable?

Does the media prefer AVBP or GRFS?

Do insiders & institutionals hold more shares of AVBP or GRFS?

Which has stronger valuation and earnings, AVBP or GRFS?

Summary

How does ArriVent BioPharma compare to CRISPR Therapeutics?

Which has more risk & volatility, AVBP or CRSP?

Which has stronger earnings and valuation, AVBP or CRSP?

Do institutionals and insiders hold more shares of AVBP or CRSP?

Is AVBP or CRSP more profitable?

Does the media prefer AVBP or CRSP?

Do analysts rate AVBP or CRSP?

Summary

How does ArriVent BioPharma compare to CG Oncology?

Do analysts recommend CGON or AVBP?

Do institutionals & insiders have more ownership in CGON or AVBP?

Which has preferable earnings and valuation, CGON or AVBP?

Is CGON or AVBP more profitable?

Does the media favor CGON or AVBP?

Which has more volatility & risk, CGON or AVBP?

Summary

How does ArriVent BioPharma compare to Xenon Pharmaceuticals?

Is XENE or AVBP more profitable?

Does the media favor XENE or AVBP?

Which has stronger valuation & earnings, XENE or AVBP?

Do insiders & institutionals believe in XENE or AVBP?

Which has more risk and volatility, XENE or AVBP?

Do analysts recommend XENE or AVBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools